Please assess the completion status of the following clinical trial:

Trial Title: H-IVIG Treatment for Severe H1N1 2009

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* (fulfill all criteria): male or female patients 18 years or older~* written informed consent by patient or next of kin (if patients too ill)~* diagnosis of H1N1 2009 infection satisfying both clinical and laboratory criteria:~  1. Laboratory criteria: at least one RT-PCR positive for H1N1 2009 from one of the clinical specimens (NPA, ETA, blood, urine or stool).~ 2. Clinical criteria: patients admitted to ICU with severe community acquired pneumonia as defined by a CURB-65 score of 3 or more~* deterioration during treatment with optimal antiviral (oral or inhaler agents only) and typical and atypical antimicrobial coverage~* required ICU and ventilatory support and within 7 days onset of symptoms.~Exclusion Criteria:~* age below 18 years~* known hypersensitivity to immune globulin or any components of the formulation~* known IgA deficiency~* acquire the H1N1 2009 infection from health care facility~* moribund patients or refusal of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous immunoglobulin (Type: ACTIVE_COMPARATOR): Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
- Hyperimmune intravenous immunoglobulin (Type: EXPERIMENTAL): Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)

Based on this trial design, predict the completion outcome and termination type (if applicable).